OPIANT PHARMACEUTICALS, INC.·4

Mar 3, 9:03 AM ET

Gorman Brian 4

4 · OPIANT PHARMACEUTICALS, INC. · Filed Mar 3, 2023

Insider Transaction Report

Form 4
Period: 2023-03-02
Transactions
  • Disposition to Issuer

    Common Stock

    2023-03-02$20.00/sh14,540$290,80017,450 total
  • Disposition to Issuer

    Common Stock

    2023-03-02$20.00/sh2,000$40,0000 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2023-03-0236,5000 total
    Exercise: $11.30From: 2021-06-01Exp: 2030-06-01Stock Option (right to buy) (36,500 underlying)
  • Award

    Common Stock

    2023-03-02+2,0002,000 total
  • Disposition to Issuer

    Common Stock

    2023-03-02$20.00/sh17,450$349,0000 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2023-03-0210,7500 total
    Exercise: $12.15Exp: 2031-01-26Common Stock (10,750 underlying)
Footnotes (5)
  • [F1]Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
  • [F2]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 17,450 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
  • [F3]2,000 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.
  • [F4]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.
  • [F5]The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

Documents

1 file
  • 4
    wf-form4_167785217715280.xmlPrimary

    FORM 4